Radius Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Radius Health, Inc.
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- NuVios, Inc.